What is Amphastar Pharmaceuticals, Inc. stock?
AMPH is the ticker symbol for Amphastar Pharmaceuticals, Inc., listed on NASDAQ.
Founded in 1996 and headquartered in Rancho Cucamonga, Amphastar Pharmaceuticals, Inc. is a Pharmaceuticals: Major company in the Health technology sector.
What you'll find on this page: What is AMPH stock? What does Amphastar Pharmaceuticals, Inc. do? What is the development journey of Amphastar Pharmaceuticals, Inc.? How has the stock price of Amphastar Pharmaceuticals, Inc. performed?
Last updated: 2026-06-01 10:08 EST
About Amphastar Pharmaceuticals, Inc.
Quick intro
Amphastar Pharmaceuticals, Inc. (AMPH) is a biopharmaceutical company specializing in technically challenging generic and proprietary injectable, inhalation, and intranasal products. Vertically integrated, it produces both finished dosage forms and active pharmaceutical ingredients (APIs).
In 2024, Amphastar achieved record performance with net revenues of $732.0 million, a 14% year-over-year increase. Full-year GAAP net income reached $159.5 million. Growth was driven by the strong integration of BAQSIMI® and record sales of Primatene MIST®, which surpassed $100 million annually, alongside a robust pipeline of biosimilars and complex generics.
Basic info
Amphastar Pharmaceuticals, Inc. Business Introduction
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a specialty pharmaceutical company dedicated to the development, manufacturing, and marketing of technically complex generic and proprietary injectable, inhalation, and intranasal products. The company differentiates itself by focusing on niche markets with high entry barriers, often involving sophisticated manufacturing processes or delivery systems.
Detailed Business Segments
1. Product Portfolio: Amphastar’s revenue is primarily driven by its diverse range of high-value products. Key products include:
· Glucagon for Injection: A vital emergency treatment for severe hypoglycemia.
· Primatene Mist: The only FDA-approved over-the-counter (OTC) epinephrine inhalation product for temporary relief of mild intermittent asthma symptoms.
· Epinephrine Pre-filled Syringes: Utilized in emergency departments and by first responders.
· Enoxaparin Sodium: A generic equivalent of Lovenox, used to prevent and treat deep vein thrombosis.
· BAQSIMI®: Acquired from Eli Lilly in 2023, this dry nasal spray for severe hypoglycemia significantly enhances the company’s proprietary branded portfolio.
2. Finished Pharmaceutical Products: This segment forms the core of the business, involving the production of complex generics that require specialized expertise in characterization and manufacturing.
3. Active Pharmaceutical Ingredients (API): Through its subsidiary, ANP (Amphastar Nanjing Pharmaceuticals), the company produces high-quality APIs, enabling vertical integration that ensures supply chain reliability and cost efficiency.
Business Model Characteristics
Vertical Integration: Amphastar oversees the entire product lifecycle, from API synthesis to finished dosage form manufacturing and distribution. This reduces reliance on third parties and improves margins.
Focus on Complexity: Instead of competing in commodity generic markets, Amphastar targets complex molecules (such as peptides and proteins) and sophisticated delivery systems (MDI, nasal sprays).
Diverse Channels: The company sells to hospitals, clinics, retail pharmacies, and wholesale distributors, maintaining broad market coverage.
Core Competitive Moat
· High Barriers to Entry: Many Amphastar products require specialized manufacturing facilities (e.g., aseptic processing) and complex regulatory submissions (ANDA for complex generics), deterring smaller competitors.
· Proprietary Technology: The company holds numerous patents and trade secrets related to inhalation and injectable delivery systems.
· Established Brand Equity: Products like Primatene Mist have a decades-long presence in the consumer market, fostering strong brand loyalty.
Latest Strategic Layout
In 2024 and 2025, Amphastar is accelerating its shift toward a branded-specialty model. The $500 million acquisition of BAQSIMI marked a transformative milestone, doubling down on the diabetes and emergency medicine sectors. Additionally, the company is heavily investing in its R&D pipeline for biosimilars and GLP-1 generic candidates, aiming to capitalize on the growing demand for weight-loss and diabetes treatments as original patents expire.
Amphastar Pharmaceuticals, Inc. Development History
Amphastar’s growth trajectory is characterized by steady organic expansion, strategic acquisitions, and a relentless commitment to technical excellence.
Development Phases
1. Foundation and Early Growth (1996 - 2005): Founded in 1996 by Dr. Jack Zhang and Dr. Mary Luo in California, the company initially focused on establishing manufacturing capabilities. Early years were spent building a portfolio of essential injectable drugs used in hospital settings.
2. Diversification and Expansion (2006 - 2013): The company expanded by acquiring manufacturing sites and establishing ANP in China to secure API supply. During this phase, Amphastar concentrated on "difficult-to-make" generics, such as Enoxaparin, which required advanced analytical testing.
3. Public Listing and Market Leadership (2014 - 2020): Amphastar went public on NASDAQ in June 2014. A key milestone was the 2018 relaunch of Primatene Mist after a multi-year hiatus to transition the product to an environmentally friendly CFC-free propellant, significantly boosting retail presence.
4. Strategic Transformation (2021 - Present): The company evolved beyond simple generics into high-value branded assets. The 2023 acquisition of BAQSIMI, the largest in company history, signaled its transformation into a diversified pharmaceutical powerhouse with significant international reach.
Analysis of Success Factors
· Technical Vision: The founders’ strong scientific background enabled the company to develop products others avoided due to technical challenges.
· Regulatory Persistence: Amphastar has demonstrated the ability to navigate the rigorous FDA approval process for complex drugs, often involving multiple review cycles.
· Financial Discipline: Maintaining a strong balance sheet and reinvesting 10-15% of revenue into R&D has sustained a robust product pipeline.
Industry Introduction
Amphastar operates within the Specialty Pharmaceutical and Complex Generic sectors. This industry differs from the broader generic market by requiring specialized expertise in delivery mechanisms and chemical characterization.
Industry Trends and Catalysts
1. The Rise of Biosimilars: As biologic drugs lose patent protection, the biosimilars market is expanding. Amphastar is well-positioned to benefit through its insulin and peptide pipelines.
2. Drug Shortages: Ongoing shortages of essential injectables in the U.S. hospital system have created stable demand for reliable manufacturers like Amphastar.
3. GLP-1 Demand: The rapid growth of GLP-1 agonists (e.g., semaglutide) presents a future "patent cliff" opportunity that specialty generic companies are preparing to address.
Competitive Landscape
Amphastar competes with both large generic manufacturers and specialty firms.
| Competitor Type | Key Players | Competitive Dynamic |
|---|---|---|
| Large Generics | Teva, Viatris, Sandoz | Broad portfolios; Amphastar competes by focusing on niche, high-margin segments. |
| Specialty Injectables | Hikma, Pfizer (Hospira) | Direct competition in hospital injectable and emergency medicine markets. |
| Branded Specialty | Eli Lilly, Novo Nordisk | Amphastar competes with branded products (such as BAQSIMI) while developing generic versions of their older drugs. |
Industry Position and Financial Highlights
Amphastar is recognized as a leader in the Emergency Medicine and Inhalation segments.
Latest Financial Data (FY 2023 - Q3 2024 Trends):
· Revenue: Amphastar reported net revenues of approximately $644 million for full-year 2023, marking a significant increase from 2022.
· Growth Drivers: BAQSIMI contributed over $50 million in a single quarter post-integration, while Primatene Mist continues to demonstrate strong year-over-year growth (around 15-20%).
· Market Cap: As of early 2024, the company’s market capitalization ranges between $2.5 billion and $3 billion, reflecting investor confidence in its transition to higher-margin branded products.
The company’s ability to sustain high gross margins (often exceeding 50%) in a generic-heavy industry underscores its successful focus on "complexity" rather than "commodity."
Sources: Amphastar Pharmaceuticals, Inc. earnings data, NASDAQ, and TradingView
Amphastar Pharmaceuticals, Inc. Financial Health Rating
Amphastar Pharmaceuticals, Inc. (AMPH) currently maintains a solid but transitioning financial profile. According to the latest fiscal year 2024 and preliminary 2025 data, the company demonstrates robust profitability and vertical integration, though it faces recent headwinds in revenue growth and earnings surprises. Based on analysis from InvestingPro and MarketBeat, the financial health is summarized below:
| Metric | Score / Value | Rating |
|---|---|---|
| Overall Financial Health Score | 78 / 100 | ⭐️⭐️⭐️⭐️ |
| Profitability (Net Margin) | 17.79% (2024 Average) | ⭐️⭐️⭐️⭐️⭐️ |
| Revenue Growth | $732.0M (2024) vs $719.9M (2025) | ⭐️⭐️ |
| Solvency (Net Debt/EBITDA) | 1.31x | ⭐️⭐️⭐️⭐️ |
| Asset Utilization (ROA) | ~1.91% - 4.11% | ⭐️⭐️⭐️ |
Key Financial Data Highlights:
• Full Year 2024: Net revenues reached $732.0 million, a 14% increase year-over-year. GAAP net income was $159.5 million.
• Full Year 2025: Preliminary results showed a slight revenue decline to $719.9 million, with GAAP net income falling to $98.1 million due to increased competition and R&D spending.
• Cash Position: As of early 2025, the company held approximately $420 million in cash and short-term investments, providing a significant buffer for pipeline development.
Amphastar Pharmaceuticals, Inc. Development Potential
1. Strategic Pivot to Proprietary and Biosimilar Products
Amphastar is undergoing a fundamental business model transformation. By 2026, the company aims to shift its pipeline from 63% generics (2021) to just 15%, while increasing proprietary products and biosimilars to 50% and 35% respectively. This shift is designed to capture higher margins and create higher barriers to entry for competitors.
2. The "Baqsimi" and "Primatene MIST" Growth Engines
• Baqsimi: Following its acquisition from Eli Lilly, Baqsimi has become a core driver. In 2025, Baqsimi sales increased by 46%, and management forecasts peak annual sales of $250 million to $275 million.
• Primatene MIST: This over-the-counter inhaler exceeded $100 million in annual sales in 2024 and continues to show high single-digit growth potential through expanded physician sampling programs.
3. High-Value Pipeline Catalysts
Amphastar’s roadmap features several major clinical and regulatory milestones:
• AMP-004 (Insulin Aspart): A biosimilar targeting a $5 billion market, with a BsUFA goal date in Q1 2026.
• AMP-007 (Inhalation Product): Targeted for a mid-2026 launch, addressing a $1.5 billion market.
• Peptide Expansion: The company recently in-licensed three novel peptide candidates targeting oncology and ophthalmology, markets with an addressable opportunity exceeding $60 billion.
Amphastar Pharmaceuticals, Inc. Pros and Risks
Company Strengths (Pros)
• Vertical Integration: Amphastar produces over 60% of its own Active Pharmaceutical Ingredients (API) in-house. This reduces supply chain volatility and protects gross margins, which have historically remained above 50%.
• Market Shortage Resilience: The company was recently recognized by the FDA with the Drug Shortage Assistance Award, highlighting its ability to capture market share when competitors face supply disruptions in critical care products like Dextrose and Sodium Bicarbonate.
• Robust Balance Sheet: With a Net Debt/EBITDA ratio of ~1.31x, the company is well-positioned to fund its expensive R&D clinical trials and potential M&A activities without significant dilution.
Company Risks
• Intense Competitive Pressure: Legacy generic products like Glucagon and Epinephrine have seen significant sales declines (36% and 25% respectively in 2025) due to new market entrants and pricing wars.
• Concentration Risk: Approximately 40% of 2024 revenue was derived from just two products: Primatene MIST and Baqsimi. Any regulatory setback or safety issue with these brands would materially impact the company.
• R&D and Regulatory Delays: The transition to biosimilars involves high capital expenditure. Delays in FDA approvals (such as the shift of some approvals to 2027) can lead to earnings misses, as seen in the Q4 2025 results where EPS of $0.73 missed the consensus estimate of $0.91.
كيف ينظر المحللون إلى شركة Amphastar Pharmaceuticals, Inc. وسهم AMPH؟
مع اقتراب منتصف عام 2024، يتميز شعور محللي وول ستريت تجاه Amphastar Pharmaceuticals (AMPH) بـ "تفاؤل حذر مع تركيز على تنفيذ خط الأنابيب". على الرغم من أن الشركة تواجه ضغوطًا تنافسية في قطاعاتها التقليدية، إلا أن تحولها الاستراتيجي نحو الأدوية الجنيسة المعقدة ذات الحواجز العالية للدخول والبيوسيميلار أبقى المحللين مهتمين. ولا تزال الاستحواذ الأخير على Baqsimi من Eli Lilly محور قصة نمو الشركة. فيما يلي تحليل مفصل لآراء المحللين السائدة:
1. وجهات النظر المؤسسية الأساسية حول الشركة
دمج الأصول الاستراتيجية: يرى معظم المحللين أن الاستحواذ على Baqsimi (شكل مسحوق جاف من الجلوكاجون) يمثل خطوة تحويلية. أشارت بنوك الاستثمار مثل Jefferies إلى أن Baqsimi يوفر لشركة Amphastar منتجًا ذا هامش ربح مرتفع ومُعلّمًا بالعلامة التجارية، مما ي diversifies تدفق إيراداتها بعيدًا عن الحقن الجنيسة ذات الهامش المنخفض. يراقب المحللون عن كثب التكامل التجاري لهذا الأصل، الذي ساهم بشكل كبير في نمو الإيرادات في الربع الأول من عام 2024.
الميزة التقنية في الأدوية الجنيسة المعقدة: يبرز المحللون التكامل الرأسي وخبرة Amphastar في المنتجات التي يصعب تصنيعها، مثل أدوية الاستنشاق والحقن. تُعتبر قدرة الشركة على اجتياز عملية الموافقة المعقدة من FDA لمنتجات مثل Glucagon وPrimatene Mist ميزة تنافسية رئيسية. وقد أكد Piper Sandler سابقًا أن قدرات التصنيع المتخصصة لدى Amphastar تجعلها أقل عرضة لتآكل الأسعار الذي يشهده السوق الجنيس الأوسع.
إمكانات خط الأنابيب: يتركز الاهتمام في الفترة 2024-2025 على خط البيوسيميلار، وبشكل خاص تطوير AMP-002 (Teriparatide) والبيوسيميلارات المحتملة للأنسولين. يعتقد المحللون أنه إذا تمكنت Amphastar من إطلاق هذه المنتجات بنجاح، فسيؤدي ذلك إلى إعادة تقييم كبيرة لقيمة السهم.
2. تقييمات الأسهم وأهداف الأسعار
حتى مايو 2024، يميل إجماع السوق على AMPH إلى "شراء معتدل" أو "شراء":
توزيع التقييمات: بين المحللين الرئيسيين الذين يغطون السهم (بما في ذلك شركات مثل Piper Sandler, Needham, وJefferies)، يحتفظ الأغلبية بتقييم "شراء" أو "زيادة الوزن". لا توجد حاليًا تقييمات "بيع" رئيسية، رغم أن بعض الشركات تحتفظ بتقييم "احتفاظ" في انتظار توجيهات أوضح بشأن المنافسة الجنيسة لمنتجاتها الرئيسية.
تقديرات أهداف الأسعار:
متوسط هدف السعر: حدد المحللون متوسط هدف سعر في نطاق 55.00 إلى 65.00 دولار، مما يمثل ارتفاعًا محتملاً بنحو 20-30% من مستويات التداول الحالية في أواخر الأربعينيات.
السيناريو المتفائل: تصل الأهداف الأكثر تفاؤلاً إلى 70.00 دولار، بناءً على تفوق مبيعات Baqsimi وتوقيت الموافقة على طلبات الجنيس الجديدة.
السيناريو المتشائم: تقدر التوقعات المحافظة بحوالي 48.00 دولار، تعكس المخاوف بشأن بطء طرح المنتجات الجديدة ونفقات البحث والتطوير التي تؤثر على هوامش الربح قصيرة الأجل.
3. عوامل المخاطر الرئيسية التي حددها المحللون
على الرغم من النظرة الإيجابية، يحذر المحللون المستثمرين من عدة تحديات:
زيادة المنافسة: لا يزال سوق الجنيس للجلوكاجون والإبينفرين مزدحمًا. أشار محللو Needham إلى أن دخول منافسين جدد قد يضغط على حصة Amphastar في السوق لمنتجاتها التقليدية، مما يستلزم الابتكار المستمر للحفاظ على الربحية.
العقبات التنظيمية: مثل جميع شركات الأدوية، تخضع Amphastar لتقلبات FDA غير المتوقعة. قد تؤدي التأخيرات في الموافقة على خط البيوسيميلار أو "رسائل الرد الكامل" (CRLs) المتعلقة بمرافق التصنيع إلى تقلبات كبيرة في السهم.
خدمة الدين: استلزم استحواذ Baqsimi تمويلًا كبيرًا. يراقب المحللون التدفق النقدي للشركة عن كثب لضمان قدرتها على خدمة ديونها بشكل مريح مع الاستمرار في تمويل خط البحث والتطوير الطموح.
الملخص
الإجماع في وول ستريت هو أن Amphastar لاعب قوي في مجال الأدوية المتخصصة. وعلى الرغم من افتقارها للحجم الضخم للعمالقة العالميين، فإن استراتيجيتها "التركيز على الفجوات" تثبت فعاليتها. بالنسبة لعام 2024، يعتقد المحللون أن السهم يمثل فرصة "نمو بسعر معقول" (GARP) قوية، شريطة أن تستمر الشركة في تحقيق نمو عالي الهامش من محفظتها ذات العلامة التجارية وتحافظ على زخمها في مجال الأدوية الجنيسة المعقدة.
Amphastar Pharmaceuticals, Inc. (AMPH) Frequently Asked Questions
What are the key investment highlights for Amphastar Pharmaceuticals, and who are its main competitors?
Amphastar Pharmaceuticals (AMPH) is a specialty pharmaceutical company focused on developing, manufacturing, and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products.
Key highlights include:
1. Strategic Acquisitions: The 2023 acquisition of BAQSIMI® from Eli Lilly has significantly boosted revenue and transformed the company's commercial profile.
2. High Entry Barriers: Amphastar specializes in complex drug-device combinations, which face less competition due to high manufacturing and regulatory hurdles.
3. Robust Pipeline: The company has multiple ANDAs (Abbreviated New Drug Applications) pending with the FDA, including biosimilar candidates like Insulin Aspart.
Main Competitors: Amphastar competes with major generic and specialty firms such as Viatris (VTRS), Hikma Pharmaceuticals, Sandoz, and Teva Pharmaceutical Industries (TEVA).
Are Amphastar’s latest financial data healthy? How are its revenue, net income, and debt?
Based on the latest financial reports (Full Year 2023 and Q1 2024 data):
Revenue: Amphastar reported record net revenues of $644.4 million for the full year 2023, a 29% increase compared to $499.0 million in 2022. This growth was largely driven by BAQSIMI and Glucagon sales.
Net Income: For the full year 2023, GAAP net income was $140.2 million ($2.68 per diluted share), compared to $91.5 million in 2022.
Debt and Liquidity: As of December 31, 2023, the company held cash, cash equivalents, and restricted cash of approximately $266 million. While the company took on debt to finance the $500 million upfront payment for BAQSIMI, its strong cash flow from operations (over $140 million in 2023) indicates a manageable leverage position.
Is the current AMPH stock valuation high? How do its P/E and P/B ratios compare to the industry?
As of mid-2024, Amphastar’s valuation reflects its transition into a high-growth specialty pharma player:
P/E Ratio: AMPH generally trades at a trailing P/E ratio between 12x and 15x. This is often considered attractive or "in-line" compared to the broader Specialty Generic Pharmaceuticals industry average, especially given its double-digit earnings growth.
P/B Ratio: The Price-to-Book ratio typically sits around 3.5x to 4.5x, reflecting the premium investors pay for its proprietary drug-delivery technologies and the high value of its newly acquired intangible assets (BAQSIMI).
How has AMPH stock performed over the past three months and the past year? Has it outperformed its peers?
Over the past year, AMPH has been a strong performer, significantly outperforming the S&P 500 and the iShares Biotechnology ETF (IBB). The stock saw a massive surge following the successful integration of BAQSIMI and positive earnings surprises.
In the past three months, the stock has experienced some volatility, consolidating after reaching 52-week highs. However, compared to peers like Viatris or Teva, Amphastar has historically shown higher price appreciation over a 3-year trailing period due to its smaller market cap and faster revenue growth trajectory.
What recent industry news or trends are affecting AMPH?
Several factors are currently influencing the stock:
1. FDA Approvals: Investors are closely watching for the approval of its AMP-004 (Intranasal Naloxone) and other complex generics.
2. Drug Pricing Legislation: Like all US pharma companies, Amphastar is subject to the impacts of the Inflation Reduction Act, though its focus on generics often provides a defensive cushion.
3. Shortages: Ongoing national shortages of injectable drugs have occasionally increased demand for Amphastar’s legacy hospital products.
Are major institutions buying or selling AMPH stock recently?
Amphastar maintains high institutional ownership, typically exceeding 60-70%. Major holders include BlackRock, Vanguard, and State Street.
Recent filings indicate a "hold" or "accumulate" sentiment among institutional investors. While there has been some profit-taking following the stock's 2023 rally, the company remains a favorite for healthcare-focused hedge funds due to its specialized niche in the respiratory and emergency injection markets.
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreStock details
How do I buy stock tokens and trade stock perps on Bitget?
To trade Amphastar Pharmaceuticals, Inc. (AMPH) and other stock products on Bitget, simply follow these steps: 1. Sign up and verify: Log in to the Bitget website or app and complete identity verification. 2. Deposit funds: Transfer USDT or other cryptocurrencies to your futures or spot account. 3. Find trading pairs: Search for AMPH or other stock token/stock perps trading pairs on the trading page. 4. Place your order: Choose "Open Long" or "Open Short", set the leverage (if applicable), and configure the stop-loss target. Note: Trading stock tokens and stock perps involves high risk. Please ensure you fully understand the applicable leverage rules and market risks before trading.
Why buy stock tokens and trade stock perps on Bitget?
Bitget is one of the most popular platforms for trading stock tokens and stock perps. Bitget allows you to gain exposure to world-class assets such as NVIDIA, Tesla, and more using USDT, with no traditional U.S. brokerage account required. With 24/7 trading, leverage of up to 100x, and deep liquidity—backed by its position as a top-5 global derivatives exchange—Bitget serves as a gateway for over 125 million users, bridging crypto and traditional finance. 1. Minimal entry barrier: Say goodbye to complex brokerage account opening and compliance procedures. Simply use your existing crypto assets (e.g., USDT) as margin to access global equities seamlessly. 2. 24/7 trading: Markets are open around the clock. Even when U.S. stock markets are closed, tokenized assets allow you to capture volatility driven by global macro events or earnings reports during pre-market, after-hours, and holidays. 3. Maximized capital efficiency: Enjoy leverage of up to 100x. With a unified trading account, a single margin balance can be used across spot, futures, and stock products, improving capital efficiency and flexibility. 4. Strong market position: According to the latest data, Bitget accounts for approximately 89% of global trading volume in stock tokens issued by platforms such as Ondo Finance, making it one of the most liquid platforms in the real-world asset (RWA) sector. 5. Multi-layered, institutional-grade security: Bitget publishes monthly Proof of Reserves (PoR), with an overall reserve ratio consistently exceeding 100%. A dedicated user protection fund is maintained at over $300 million, funded entirely by Bitget's own capital. Designed to compensate users in the event of hacks or unforeseen security incidents, it is one of the largest protection funds in the industry. The platform uses a segregated hot and cold wallet structure with multi-signature authorization. Most user assets are stored in offline cold wallets, reducing exposure to network-based attacks. Bitget also holds regulatory licenses across multiple jurisdictions and partners with leading security firms such as CertiK for in-depth audits. Powered by a transparent operating model and robust risk management, Bitget has earned a high level of trust from over 120 million users worldwide. By trading on Bitget, you gain access to a world-class platform with reserve transparency that exceeds industry standards, a protection fund of over $300 million, and institutional-grade cold storage that safeguards user assets—allowing you to capture opportunities across both U.S. equities and crypto markets with confidence.